Communiqués Elutia Inc.

Actions

ELUT

US05479K1060

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
3,41 ^USD	+0,29 %		+4,92 %	+57,87 %

09/05	Elutia Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/05	Transcript : Elutia Inc., Q1 2024 Earnings Call, May 09, 2024

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024	13/05	AQ
Elutia : Q1 2024 Financial Results Presentation	09/05	PU
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance	09/05	AQ
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024	02/05	AQ
Elutia Planet MicroCap Showcase: VEGAS 2024 Presentation	02/05	PU
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1	24/04	AQ
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024	07/03	AQ
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024	22/02	AQ
Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants	20/02	AQ
Elutia Regains Compliance with Nasdaq Listing Requirements	10/01	AQ
Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance	18/12	AQ
Elutia : The Wall Street Transcript	05/12	PU
Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results	13/11	AQ
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million	09/11	AQ
Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	06/11	AQ
Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices	06/09/23	AQ
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures	30/08/23	AQ
Aziyo Biologics : 2Q 2023 Financial Results Presentation	15/08/23	PU
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company	14/08/23	AQ
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023	31/07/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Elutia Inc.

Actions

ELUT

US05479K1060

Communiqués

Filtres